Zoar Limited (NYSE:ZOAR)
| Market Cap | $703.80M-40.2% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 180.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,967 |
| Open | $5.15 |
| Previous Close | $6.39 |
| Day's Range | $3.75 - $5.33 |
| 52-Week Range | $3.75 - $6.72 |
| Beta | n/a |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
About ZOAR
Zoar Limited, a pharmaceutical company, focuses on the development and manufacture of active pharmaceutical ingredients. It also provides contract development and manufacturing services to pharmaceutical and biotechnology companies worldwide. The company was founded in 2012 and is headquartered in Grand Cayman, the Cayman Islands.
$ZOAR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ZOAR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ZOAR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ZOAR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ZOAR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ZOAR from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ZOAR’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.
